BMY · NYSE · STOCK
Bristol Myers Squibb (BMY) Stock Analysis
$59.11
52W $42.52 – $68.64
54/100
$120.77B
13.0
0.23
Is BMY Bullish or Bearish?
Mixed.
Innellis AI committee rates Bristol Myers Squibb (BMY) Watch with a composite score of 54/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.50 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.50 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 99.3% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 2.44) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 13.0 is inexpensive for the broad market — Value
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Dividend yield of 4.6% pays you to wait — Value
- EPS growing 99.3% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Debt-to-equity of 2.44 adds balance-sheet risk to the value case — Value
- RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
54/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 68%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 13.0 is inexpensive for the broad market
− Price-to-book of 5.9x prices in significant intangible value
Growth Analyst
bullish
72
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 99.3% YoY
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 97 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.8 to 54.5.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Technical Analyst: stance neutral->bearish; score 48->38 (-10); +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
28.2
Oversold
MACD Histogram
-0.298
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$58.62
Resistance
$60.20
Bollinger %B
0.10
Inside Bands
Price vs Moving Averages
EMA 9
$60.32
Below
EMA 21
$61.71
Below
EMA 50
$62.49
Below
EMA 200
$59.17
Below
Fundamental Analysis
Valuation
80
Growth
87
Profitability
93
Financial Health
45
Cash Flow
70
Valuation
P/E Ratio
13.0×
P/B Ratio
5.41×
PEG Ratio
0.16
Dividend Yield
4.26%
52W High
$68.64
52W Low
$42.52
Quality & Growth
ROE
3818.5%
ROA
783.5%
Gross Margin
7015.7%
Operating Margin
2814.2%
Revenue Growth YoY
—
Debt / Equity
1.93
AI Fundamental Assessment
P/E ratio of 13.0 (inexpensive relative to a 15-40x range); Price-to-book of 5.4x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 38.2%; Return on assets of 7.8%; Net margin of 18.9%; Gross margin of 70.2%; Current ratio of 1.53 (healthy short-term liquidity); Debt-to-equity of 1.93; Free cash flow per share is positive (5.60); Most recent quarter beat estimates by 27.2%; 5 consecutive earnings beats; EPS growth accelerating (+25.4% -> +29.1% QoQ); Average YoY EPS growth of 39.7%; Analyst estimates rising over recent quarters
Get the Full BMY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →